A Study With GLPG1972 in Osteoarthritis Subjects

November 21, 2017 updated by: Galapagos NV

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis

This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized in a 4:1 allocation ratio to active treatment with GLPG1972 or matching placebo. In each cohort, OA subjects will be stratified for age (50- 64 years and 65-75 years) with a minimum of 2 of each sex per age group.

Study Overview

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Daytona Beach, Florida, United States, 32117
        • Covance Daytona Beach

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Male or female subjects of non-childbearing potential, 50-75 years of age on the date of signing the Informed Consent Form (ICF), inclusive extremes.
  2. Diagnosis of OA (knee and/or hip) made by their physician based on symptoms, clinical signs and documented historical imaging evidence.
  3. A body mass index (BMI) between 18.0 and 34.9 kg/m2, inclusive extremes.
  4. Judged to be in age-appropriate good health by the investigator based upon the results of a medical history, physical examination, vital signs and 12-lead ECG, and fasting clinical laboratory profile.
  5. Subjects with a stable chronic illness at least 3 months will be accepted subject to the investigator's judgment.

Exclusion Criteria:

  1. Administration of intraarticular glucocorticoid injections or hyaluronan injections in the last 3 months prior to study screening.
  2. Subjects who underwent or are on a waiting list for total hip or knee replacement and any other surgery planned during the study (up to Day 50).
  3. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
  4. Positive serology for HBsAg or HCV antibody or history of hepatitis from any cause with the exception of hepatitis A.
  5. History of or a current immunosuppressive condition.
  6. Clinically significant serious, per investigator's discretion, and/or unstable illness in the 3 months before screening
  7. Renal function with an estimated creatinine clearance < 60 mL/min based on the Cockcroft-Gault formula. Retesting is allowed once (see Section 5.2).
  8. Use of verapamil, diltiazem, amitriptyline, warfarin, acenocoumarol, phenobarbital and phenytoin, within 4 weeks before first study drug administration
  9. Consumption of herbal medications that are strong inhibitors and/or inducers of CYPs (e.g., St. John's Wort) and grapefruit/grapefruit products, Seville oranges, or any poppy seed, within 7 days prior to the first study drug administration.
  10. History of solid organ or hematopoietic cell transplantation.
  11. History of malignancy within the past 5 years.
  12. Clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction (e.g., QTcF ≥ 450 ms for males and QTcF ≥ 470 ms for females, or a known long QT syndrome).
  13. Significant blood loss (including blood donation [> 450 mL]), or transfusion of any blood product within 12 weeks prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Matching placebo provided as oral tablets q.d.
Experimental: GLPG1972
GLPG1972 dose 1 provided as oral tablets q.d.
GLPG1972 dose 2 provided as oral tablets q.d.
GLPG1972 dose 3 provided as oral tablets q.d.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events
Time Frame: From screening until the final follow up visit (day 50)
To assess safety and tolerability of GLPG1972 in OA patients
From screening until the final follow up visit (day 50)
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs
Time Frame: From screening until the final follow up visit (day 50)
To assess safety and tolerability of GLPG1972 in OA patients
From screening until the final follow up visit (day 50)
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations
Time Frame: Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)
To assess safety and tolerability of GLPG1972 in OA patients
Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination
Time Frame: Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50
To assess safety and tolerability of GLPG1972 in OA patients
Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG
Time Frame: Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)
To assess safety and tolerability of GLPG1972 in OA patients
Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment
Time Frame: Day -1 to days 1 and Day 10 to day 11
To assess safety and tolerability of GLPG1972 in OA patients
Day -1 to days 1 and Day 10 to day 11
The maximum observed plasma concentration of GLPG1972 (Cmax)
Time Frame: Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
To assess PK of GLPG1972 in OA patients
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
The time (tmax) to reach Cmax of GLPG1972
Time Frame: Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
To assess PK of GLPG1972 in OA patients
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
The plasma concentration of GLPG1972 24 after the last dose
Time Frame: Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
To assess PK of GLPG1972 in OA patients
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
The area under the plasma concentration time curve from time 0 until the last quantifieble dose
Time Frame: Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
To assess PK of GLPG1972 in OA patients
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage reduction of neo-epitope ARGS vs baseline
Time Frame: Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)
To assess PD of GLPE1972 in OA patients
Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Ann Fieuw, MD, MSc, Galapagos NV

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 15, 2017

Primary Completion (Actual)

October 25, 2017

Study Completion (Actual)

October 25, 2017

Study Registration Dates

First Submitted

October 11, 2017

First Submitted That Met QC Criteria

October 11, 2017

First Posted (Actual)

October 16, 2017

Study Record Updates

Last Update Posted (Actual)

November 24, 2017

Last Update Submitted That Met QC Criteria

November 21, 2017

Last Verified

November 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • GLPG1972-CL-104

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis

Clinical Trials on GLPG1972 cohort 1

3
Subscribe